At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 62 enrolled
Drug / intervention
QVA149 +1 moredrug
Likely dose
QVA149 50 µgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Double-blinded, Single-center, Placebo Controlled, Cross-over Study to Assess the Effect of QVA149 (Indacaterol Maleate / Glycopyrronium Bromide) on Cardiac Function in Patients With Chronic Obstructive Pulmonary Disease (COPD)
In Brief
A Phase 4 clinical trial evaluating QVA149 and Placebo for Chronic Obstructive Pulmonary Disease, COPD. Completed, enrolled 62 participants across 1 site.
Detailed Summary
This mechanistic study is a single-center, randomized, double-blind, placebo-controlled, cross-over study to evaluate the effect of dual bronchodilation with QVA149 on cardiac and lung function parameters in hyperinflated COPD patients.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesGermany
Collaborators--
Timeline
Phase 4CompletedFinished
20162017201820192020202120222023202420252026
First PostedMay 2015
Enrollment StartMay 2015
Primary CompletionApr 2017
Study CompletionMay 2017
TodayJul 2026
First PostedMay 13, 2015
Enrollment StartMay 18, 2015
Primary CompletionApr 20, 2017
Study CompletionMay 15, 2017
TodayJul 2, 2026
Enrollment to primary: 1.9 yearsPosted 11.1 years ago
Interventions
QVA149drug
QVA149 capsules 100/50 µg for inhalation via Concept-1-inhaler, taken once daily
Placebodrug
Placebo to QVA140 capsules 100/50 µg for inhalation via Concept-1-inhaler, taken once daily